HONG KONG and SHANGHAI and FLORHAM PARK, N.J., March 23, 2026 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM:HCM; ...
—This large, population-based study of patients with PP-DLBCL assessed prognostic factors and confirmed that certain common therapeutic interventions can modify disease progression. Being age 65 years ...
New DLBCL trials test bispecifics with chemo, BTK add-ons, and MRD-guided preemptive allo CAR-T to cut relapse risk. The ...
Treating Patients with Primary Refractory DLBCL — or Those Who Relapse After Initial Treatment How Can Biomarkers Help Individualize Treatment of Diffuse Large B-cell Lymphoma? Using Biomarkers to ...
Study identified seven distinct and unique microenvironments within diffuse large B-cell lymphoma (DLBCL) Immune-privileged DLBCLs contain many T cells mixed with tumor B cells and show signs that ...
Hosted on MSN
Immune cell pockets found in lymphoma tumors offer new targets for personalized therapies
Subscribe to our newsletter for the latest sci-tech news updates. The study, published in Nature Genetics, was co-led by Michael Green, Ph.D., professor of Lymphoma/Myeloma, and Linghua Wang, MD, Ph.D ...
CD19-directed CAR T-cell therapy can lead to sustained remission in DLBCL, but relapse is common, affecting up to 60% of patients. Epcoritamab, a bispecific T-cell engager, may enhance CAR T-cell ...
Genmab A/S (Nasdaq: GMAB) today announced topline results from the Phase 3 EPCORE DLBCL-1 trial evaluating epcoritamab, a T-cell engaging bispecific antibody administered subcutaneously, which ...
NORTH CHICAGO, Ill., Jan. 16, 2026 /PRNewswire/ -- AbbVie (NYSE: ABBV) today announced topline results from the Phase 3 EPCORE® DLBCL-1 trial evaluating epcoritamab, a T-cell engaging bispecific ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results